Human leukocyte antigen class II peptide-binding groove (HLA-II groove)

The Human Leukocyte Antigen (HLA) class II peptide-binding groove is a specialized structural domain located on the surface of MHC class II molecules, primarily HLA-DR, HLA-DQ, and HLA-DP (UniProt: P01903). It is formed by the folding of the alpha-1 and beta-1 domains, creating an open-ended cleft that accommodates peptides of varying lengths, typically 13 to 25 amino acids (PubMed: 25210166). The primary biological function of this groove is to bind exogenous peptides and present them to CD4+ T-helper cells, which is essential for the initiation of the adaptive immune response (StatPearls: NBK541061). In the context of disease, specific genetic variations in the amino acid sequence of the groove are strongly linked to the development of autoimmune disorders, such as Rheumatoid Arthritis and Type 1 Diabetes, where the groove mistakenly presents self-antigens (NIH: PMC3071334). This makes the groove a high-value therapeutic target for immunomodulatory agents that aim to block the presentation of pathogenic peptides. Drugs like Glatiramer acetate interact with the HLA-DR groove to compete with myelin-derived peptides, thereby reducing the autoimmune attack in Multiple Sclerosis (PubChem: CID 3081923). Additionally, small molecule inhibitors are being researched to specifically fit into the pockets of the groove to prevent the activation of autoreactive T cells (PubMed: 29038207). The high degree of polymorphism in HLA genes across the human population presents a significant challenge for drug development, as a single drug may not be effective for all patients (PubMed: 11781273).

Other names

MHC class II peptide-binding cleftHLA class II binding pocketMajor histocompatibility complex class II grooveHLA-DR/DQ/DP binding site

Competitive inhibition of peptide binding to the MHC class II cleft and modulation of CD4+ T-cell receptor recognition.